Nucleos(t)ide analogs continuation is not associated with a lower risk of HBsAg seroreversion follow...
Nucleos(t)ide analogs continuation is not associated with a lower risk of HBsAg seroreversion following PEG-IFN-induced HBsAg loss
About this item
Full title
Author / Creator
Gao, Na , Wu, Haishi , Li, Bin , Yu, Huiying , Wu, Lili , Zhang, Jing , Zhang, Nan , Lin, Bingliang , Zhao, Qiyi and Gao, Zhiliang
Publisher
England: BioMed Central
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central
Subjects
More information
Scope and Contents
Contents
It is unclear whether nucleos(t)ide analogs (NUCs) continuation provides clinical benefits following HBsAg seroclearance with pegylated interferon (PEG-IFN)-based therapy. This study aims to investigate the role of NUCs continuation in HBsAg seroreversion.
Patients who experienced serum HBsAg loss after PEG-IFN-based therapy were enrolled and fo...
Alternative Titles
Full title
Nucleos(t)ide analogs continuation is not associated with a lower risk of HBsAg seroreversion following PEG-IFN-induced HBsAg loss
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_8f667c495ae84e56a0e1b8edbe5d3a0a
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_8f667c495ae84e56a0e1b8edbe5d3a0a
Other Identifiers
ISSN
1743-422X
E-ISSN
1743-422X
DOI
10.1186/s12985-025-02700-2
